Table 1 —

Characteristics at randomization, by self-reported ethnic group, of type 2 diabetic patients in the UKPDS cohort followed for at least 3 years

WCACIA
n2,484265250
Patients in main randomization (%)83.484.288.4
Allocated therapy: diet; insulin; sulphonylurea; metformin (%)22; 28; 39; 1119; 29; 42; 1025; 30; 39; 5
Age (years)*  53 ± 9  51 ± 7§48 ± 8§
Male (%)*565476§
Body weight (kg)  77 ± 16 75 ± 13 69 ± 12§
BMI (kg/m2)27.5 ± 5.327.0 ± 4.5  25.3 ± 3.8§
FPG (mmol/l)8.8 (7.5–11.7)9.1 (7.7–12.0)8.6 (7.5–10.7)
HbA1c(%)*7.3 (6.3–8.8)7.9 (6.6–9.5)7.2 (6.4–8.6)
Plasma insulin (pmol/l)*90 (50–163)78 (44–139)§105 (64–173)§
β-cell function (%)*47 (28–69)41 (24–61)52 (34–73)
Insulin sensitivity (%)*55 (39–80)59 (46–90)§50 (36–66)§
Hypertensive: not; untreated; treated (%)*59; 23; 1858; 22; 2078; 14; 9§
Systolic blood pressure (mmHg)*137 ± 20  137 ± 19125 ± 16§
Diastolic blood pressure (mmHg)* 83 ± 10  85 ± 1080 ± 9§
Plasma total cholesterol (mmol/l)* 5.5 ± 1.2  5.3 ± 1.1§5.2 ± 1.0§
Plasma LDL cholesterol (mmol/l)* 3.6 ± 1.1  3.5 ± 1.13.3 ± 0.9§
Plasma HDL cholesterol (mmol/l)* 1.07 ± 0.24  1.19 ± 0.25§ 1.01 ± 0.21§
Plasma triglyceride (mmol/l)*1.6 (1.0–2.7) 1.1 (0.7–1.7)§1.7 (1.0–2.8)
  • Data are means ± SD, geometric means (± 1 SD interval), medians (interquartile range), or %.

  • *

    * P < 0.00001 by Kruskal-Wallis or χ2 test;

  • SBP > 160 mmHg or DBP > 90 mmHg;

  • P < 0.01 vs. WC;

  • §

    § P < 0.001 vs. WC;

  • P < 0.01 vs. AC;

  • P < 0.001 vs. AC.